Radialogica
Radialogica provides cloud-based software and clinical trial services for radiotherapy quality management in cancer care. It serves pharmaceutical and biotech sponsors, CROs, medical device manufacturers, and radiation oncology clinics globally through its SciMoCa and fullAccess products.
- Company typePrivate
- Founded2011
- HeadquartersClarkton, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Radialogica does
Radialogica is a US-based healthtech company that provides software and services for radiotherapy (RT) quality management in cancer care. Founded in 2011 and headquartered in Clayton, Missouri, the company addresses variability in radiation therapy treatment planning and delivery that can affect tumor control, toxicity, and patient outcomes. It serves four primary customer segments: pharmaceutical and biotech study sponsors, contract research organizations (CROs), radiation oncology clinics and hospitals, and medical device manufacturers. Radialogica reports a global footprint spanning more than 600 clinical sites across 50+ countries, with software installed at 225+ sites impacting over 1.5 million patient treatments, and more than 10,000 DICOM-RT case submissions processed to date.
The company's core technology stack consists of two products. SciMoCa™ is a Monte Carlo-based secondary dose calculation and patient QA tool, co-developed with Prof. Dr. Markus Alber and Scientific RT, combining Monte Carlo physics accuracy with custom beam model precision and supporting all major linear accelerators including Elekta Unity MR-Linac, Varian Ethos, CyberKnife, TomoTherapy, and Radixact. fullAccess™ is a radiotherapy data display, communication, and analysis platform supporting multi-modality imaging and multi-vendor treatment plan viewing, with benchmarking capabilities. The underlying infrastructure is a proprietary, GxP-compliant cloud platform purpose-built for radiotherapy data acquisition and analysis, certified to ISO 13485:2003, with fullAccess holding EU MDR certification and CE marking.
Radialogica generates revenue across three streams. Clinical trials services provide RT QA program design, treatment guideline development, data collection, dosimetric evaluation, and prospective/retrospective case reviews for pharma, biotech, and device sponsors on a professional services basis. Clinical software licensing covers SciMoCa and fullAccess deployed within clinics and across networks on subscription/recurring terms. OEM distribution royalties flow from an exclusive global agreement with Sun Nuclear (Mirion Medical Company) to distribute SciMoCa for online adaptive systems and to embed the algorithm into the SunCHECK Platform as DoseCHECK Monte Carlo. Go-to-market combines direct enterprise sales with channel-led distribution through Sun Nuclear, Perceptive Imaging, and Clario, supported by content marketing, joint webinars, and clinical trial partnerships.
Radialogica firmographics
Firmographics- Name
- Radialogica
- Legal name
- Radialogica
- Website
- https://radialogica.com
- Company type
- Private
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Radialogica provides cloud-based software and clinical trial services for radiotherapy quality management in cancer care. It serves pharmaceutical and biotech sponsors, CROs, medical device manufacturers, and radiation oncology clinics globally through its SciMoCa and fullAccess products.
- Ownership category
- akta.pro rank
Radialogica industry classification
Industry- Product category
- Radiation Oncology Software
- NAICS
- Computer Systems Design and Related Services (54151), Other Scientific and Technical Consulting Services (54169), Scientific Research and Development Services (5417)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Services-Health Services (8000)
- akta.pro primary industry
- Radiation Therapy Planning & Simulation Imaging (CT Sim/MR Sim) (HLAHABAH)
- akta.pro secondary industries
- Radiation Dose Management & Analytics (HLACALAH), Randomization & Trial Supply Management (RTSM/IRT/IVRS/IWRS) (HLACAOAC)
Keywords
Where Radialogica is headquartered
LocationHeadquarters
- HQ city
- Clarkton
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Radialogica business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Clinical Trials Services: Services for pharma, biotech, and medical device manufacturers including RT QA program design, RT treatment guidelines development, data collection and curation, dosimetric evaluation, and prospective/retrospective case reviews. Revenue from professional services spanning study design through regulatory reporting.
- Clinical Software Licensing: Software products (SciMoCa, fullAccess) deployed within clinics and across networks. Licensed to healthcare providers for treatment plan QA, physician plan review, and plan quality evaluation. Revenue from software licensing and distribution.
- OEM Distribution (Sun Nuclear): Exclusive global distribution agreement enabling Sun Nuclear to distribute SciMoCa software and integrate the dose calculation algorithm into SunCHECK Platform. Revenue from licensing and distribution partnerships.
Go-to-market motion3 records
Distribution channels3 records
Marketing channels4 records
Radialogica product offering
Product offeringCore offering
Radialogica provides proprietary clinical software (SciMoCa™ Monte Carlo dose calculation and fullAccess™ radiotherapy data platform) and professional services for radiotherapy quality management in oncology. The software enables independent secondary dose calculation, treatment plan QA, and multi-vendor radiotherapy data sharing within clinics and networks; the services arm designs and runs RT QA programs for pharma, biotech, medical device, and CRO sponsors of oncology clinical trials, including RT guideline development, DICOM-RT data collection, dosimetric evaluation, and prospective/retrospective case reviews.
Product overview
Radialogica offers two core clinical software products: SciMoCa™ and fullAccess™. SciMoCa™ is a Monte Carlo-based secondary dose calculation and plan QA tool that integrates into clinical IT infrastructure and is also distributed through the Sun Nuclear SunCHECK Platform. fullAccess™ is a radiotherapy data display, communication, and analysis platform for multi-modality image and plan viewing, plan quality benchmarking, and clinical data sharing. Both products serve radiation oncology clinics and clinical trials for treatment quality management.
Differentiator
Problem solved
Functional benefit
Brands
- SciMoCa™: Monte Carlo-based solution for independent dose calculation and plan QA. Developed in collaboration with Prof. Dr. Markus Alber and ScientificRT, combines Monte Carlo accuracy with custom beam models for robust dose verification and plan quality evaluation.
- fullAccess™
- DoseCHECK Monte Carlo
Products and services
- SciMoCa™ Monte Carlo-based clinical software tool for independent secondary dose computation and radiotherapy treatment plan quality assurance. Supports photon and electron Monte Carlo dose calculation, machine-specific and generic beam data models, comparative plan quality metrics, 3D gamma analysis, and real-time online adaptive planning for Elekta Unity MR-Linac and Varian Ethos. Developed in collaboration with Prof. Dr. Markus Alber and Scientific RT and distributed globally via Sun Nuclear (Mirion Medical Company) as DoseCHECK Monte Carlo inside the SunCHECK Platform. For radiation oncology clinics, hospital networks, and clinical trial sponsors.
- fullAccess™ Fully integrated radiotherapy data display, communication, and analysis platform that enables clinicians across the continuum of care to access, analyze, and share RT data. Supports flexible viewing of multi-modality diagnostic images and multi-vendor treatment plans, extraction and benchmarking of plan quality metrics, and sharing of RT data between facilities and caregivers for clinical collaboration. EU MDR–certified medical software. For radiation oncology clinics, hospital networks, and clinical trial sponsors.
- Clinical Trials Services — Radiotherapy Quality Management for Oncology Trials Professional services in which Radialogica partners with study sponsors and CROs to manage the quality of radiation therapy in oncology clinical trials. Engagement scope includes RT QA program design and implementation, RT treatment guideline development, RT data collection and aggregation (DICOM-RT), extraction and evaluation of dosimetric parameters and clinical quality measures, and prospective or retrospective case reviews and reporting. For pharmaceutical and biotech sponsors, CROs, and medical device manufacturers running oncology trials with on-study or prior radiation therapy.
Quantifiable outcome
- 32% of patients in clinical trials have non-per-protocol RT treatment plans, with almost two-fold increase in risk of tumor recurrence and mortality compared to per-protocol plans (meta-analysis of cooperative group clinical trials)
Companies that use Radialogica
Customer profileNamed customers6 records
Segments4 records
Ideal customer profiles4 records
Radialogica technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
Feature5 records
Radialogica partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered supporting, major and core.
- Aarhus University HospitalsupportingDepartment of Oncology conducted research quantifying benefits of Monte Carlo dose computation over analytical algorithms and benefit of custom beam models. Results published in Journal of Applied Clinical Medical Physics.
- ClariomajorCollaboration expanding Clario's oncology trial support through integration of Radialogica's enhanced radiation therapy quality control. Clario now offers centralized expert-led review of RT plans and treatment delivery covering both concurrent and prior radiotherapy.
- Society of Interventional Oncology (SIO)coreSelected by SIO to provide data collection, curation and analytics services for the TRIBUTE trial - prospective multi-center observational study evaluating patients with symptomatic high-risk bone metastases treated with percutaneous ablation and palliative radiation therapy.
- Varian (Siemens Healthineers)supportingTRIBUTE trial industry partner. Varian supported collaboration providing radiotherapy treatment technology for metastatic bone disease study evaluating ablation and radiation therapy outcomes.
- Stryker, Inc.supportingTRIBUTE trial industry partner for multi-center study evaluating patients with metastatic bone disease treated with percutaneous ablation and palliative radiation therapy.
- Boston Scientific CorporationsupportingTRIBUTE trial industry partner for multi-center study evaluating patients with metastatic bone disease treated with percutaneous ablation and palliative radiation therapy.
- Perceptive ImagingmajorRadialogica joined Perceptive's supplier network to enhance service delivery, enabling Perceptive to extend Radialogica's radiation therapy quality management services to global trial sponsors with concurrent or prior radiotherapy treatment in oncology studies.
- Sun Nuclear (Mirion Medical Company)coreGlobal agreement enabling Sun Nuclear to exclusively distribute Radialogica's SciMoCa software for secondary dose computation and patient-specific quality assurance for online adaptive systems. Sun Nuclear also integrates the SciMoCa dose calculation algorithm into the SunCHECK Platform as DoseCHECK Monte Carlo.
- IRCCS Sacro Cuore-Don Calabria Cancer Care CentersupportingPre-clinical validation partner for SciMoCa on Elekta Unity MR-Linac. Successfully validated accuracy and integration within real-time adaptive workflow.
- Scientific RTcoreJoint development and distribution partnership for SciMoCa Monte Carlo dose calculation algorithm. SciMoCa developed in collaboration with Prof. Dr. Markus Alber and ScientificRT. Global agreement for integration into Sun Nuclear SunCHECK Platform.
Scale indicators5 records
Recent moves6 records
Expansion highlights6 records
Radialogica competitors and assessment
Company assessmentDirect peers
- PTW Freiburg: Medical dosimetry specialist offering detectors, phantoms, and QA software used by radiation oncology departments and clinical trial sponsors — competing for the same hospital QA and trial RT QA budgets as Radialogica.
- Standard Imaging: Long-established supplier of QA phantoms, electrometers, and patient-specific QA software for radiotherapy — overlapping directly with Radialogica's plan QA and dose verification use cases in radiation oncology clinics.
- IBA Dosimetry: Global radiotherapy QA and dosimetry vendor offering independent dose verification, beam QA, and patient plan checks — directly comparable to SciMoCa for clinics and trials requiring independent Monte Carlo-style dose computation.
- Sun Nuclear (Mirion Medical): Mirion's Sun Nuclear division is both Radialogica's exclusive global distributor and a direct competitor in patient-specific QA and dose verification through the SunCHECK Platform, including the DoseCHECK Monte Carlo product built on SciMoCa itself.
- RaySearch Laboratories: Vendor of treatment planning and plan QA software (RayStation, RayCare, RayIntelligence) serving many of the same radiation oncology clinics and trial sponsors, with overlapping plan quality and analytics use cases.
Broad incumbents
- Elekta: Radiotherapy OEM behind the Unity MR-Linac, where Radialogica's SciMoCa serves as a key independent QA tool; Elekta's own QA software roadmap directly competes with third-party dose verification.
- Varian (Siemens Healthineers): Dominant radiotherapy OEM (linacs, Ethos adaptive platform, Eclipse TPS) that ships its own QA/dose verification tools and increasingly bundles RT analytics — overlapping with fullAccess and SciMoCa across the same customer base.
Emerging players
- CIRS (Computerized Imaging Reference Systems): Supplier of QA phantoms, tissue-equivalent technology, and simulation products used in radiation oncology QA workflows — adjacent competitor for clinic-level RT quality assurance budgets.
- MIM Software: Medical imaging analytics platform widely used in radiation oncology for image fusion, contouring, and dose review; competes with fullAccess for the multi-modality RT data display and analysis use case.
- Mirada Medical: Imaging software specialist with oncology and RT modules for plan review and multi-modality viewing; comparable to fullAccess's radiotherapy data display and clinical collaboration positioning.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights6 records
Customer concentration
Radialogica social profiles
Digital presenceRadialogica compliance and trust
Trust signalCompliance2 records
Radialogica financial estimates
Financial estimateRevenue estimate
Valuation estimate
Radialogica leadership team
Management profileNumber of profiles
Profiles5 records
Radialogica funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Radialogica M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Radialogica
What does Radialogica do?
Radialogica provides proprietary clinical software (SciMoCa™ Monte Carlo dose calculation and fullAccess™ radiotherapy data platform) and professional services for radiotherapy quality management in oncology. The software enables independent secondary dose calculation, treatment plan QA, and multi-vendor radiotherapy data sharing within clinics and networks; the services arm designs and runs RT QA programs for pharma, biotech, medical device, and CRO sponsors of oncology clinical trials, including RT guideline development, DICOM-RT data collection, dosimetric evaluation, and prospective/retrospective case reviews.
Is Radialogica a public or private company?
Radialogica is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Radialogica founded?
Radialogica was founded in 2011. It employs 11 to 50 people.
Where is Radialogica based?
Radialogica is headquartered in Clarkton, United States, in the North America region.
How does Radialogica make money?
Three revenue lines are on record. Clinical Trials Services are the primary driver. The others are clinical Software Licensing and OEM Distribution (Sun Nuclear).
Who are Radialogica's main competitors?
Direct peers on record are PTW Freiburg, Standard Imaging, IBA Dosimetry, Sun Nuclear (Mirion Medical) and RaySearch Laboratories. Broad incumbents are Elekta and Varian (Siemens Healthineers). Emerging players are CIRS (Computerized Imaging Reference Systems), MIM Software and Mirada Medical.
Does Radialogica have an API?
No public API is recorded for Radialogica.
What industry is Radialogica in?
Radialogica's product category is Radiation Oncology Software. Its primary akta.pro industry code is HLAHABAH, Radiation Therapy Planning & Simulation Imaging (CT Sim/MR Sim), with a secondary code of HLACALAH, Radiation Dose Management & Analytics. Its NAICS code is 54151 and its SIC code is 3841.